MESO_BRAIN · Project

3D Lab-Grown Brain Networks for Faster Drug Testing and Neurological Research

healthPrototypeTRL 4

Imagine trying to test brain drugs on cells that are flat on a petri dish — it's like testing a car engine on a drawing instead of the real thing. This project built tiny 3D scaffolds, printed with ultra-precise lasers, where human stem cells grow into realistic miniature brain networks. These mini-networks fire and connect like actual brain tissue, so researchers can watch them work and test drugs on something that behaves much closer to a real human brain. The long-term goal is that one day, doctors could grow replacement neural tissue from a patient's own cells to treat conditions like Parkinson's or dementia.

By the numbers

consortium partners across 3 countries

SME industry partners (43% industry ratio)

total project deliverables produced

15 years

projected timeline for patient-specific neural implants

The business problem

What needed solving

Pharmaceutical companies spend billions testing neurological drugs on flat cell cultures and animal models that poorly predict human outcomes, leading to high failure rates in clinical trials. There is no commercially available, reproducible 3D human neural network that mimics real brain architecture for reliable drug screening. This means potential treatments for Alzheimer's, Parkinson's, and other brain diseases are delayed or abandoned due to inadequate testing platforms.

The solution

What was built

The project produced 12 deliverables including a physiological chamber for maintaining and monitoring 3D neural networks, femtosecond laser-printed nano-scale scaffolds for growing stem cell-derived neurons in defined architectures, and methods for electrical stimulation, recording, and light sheet imaging of the resulting networks.

Audience

Who needs this

Pharmaceutical companies with neurology drug pipelinesContract research organizations (CROs) offering preclinical brain testing servicesBiotech startups developing stem cell therapies for neurological conditionsAcademic core facilities and neuroscience research labsMedical device companies developing brain-computer interfaces

Business applications

Who can put this to work

Pharmaceutical Drug Discovery

enterprise

Target: Mid-to-large pharma companies with neurology pipelines (Alzheimer's, Parkinson's, dementia)

If you are a pharma company struggling with high failure rates in neurological drug trials because your preclinical models don't predict human outcomes — this project developed 3D human neural networks grown on reproducible laser-printed scaffolds that mimic brain cortical architecture. These networks display realistic connectivity and activity, enabling you to screen drug candidates on tissue that behaves like actual human brain. The consortium includes 3 SME partners with manufacturing capability, suggesting a path to scalable scaffold production.

Contract Research Services

mid-size

Target: CROs and preclinical testing labs specializing in neuroscience assays

If you are a contract research organization looking to differentiate your neuroscience testing portfolio — this project built a physiological chamber system paired with 3D stem cell-derived neural networks that allow simultaneous electrical stimulation, recording, and light sheet imaging. This means you could offer clients a premium assay platform for testing neurological compounds on reproducible human neural tissue rather than flat cell cultures. The 7-partner consortium across 3 countries developed methods designed for large-scale scaffold fabrication.

Regenerative Medicine and Cell Therapy

any

Target: Biotech companies developing stem cell-based therapies for brain injuries or neurodegenerative disease

If you are a biotech company working on cell therapies for neurological conditions and facing the challenge that transplanted neurons fail to integrate with existing brain tissue — this project addressed exactly that problem by growing stem cell-derived neurons in 3D architectures that mimic brain cortical modules. The objective describes a 15-year vision for patient-specific iPSC-derived networks for re-implantation to treat Parkinson's disease, dementia, and trauma. The underlying scaffold and cell-seeding technology could accelerate your own implantable neural tissue development.

Frequently asked

Quick answers

What would it cost to license or access this technology?

Based on available project data, specific licensing terms or pricing are not disclosed. The coordinator is Aston University (UK), a public university, which typically licenses through its technology transfer office. With 3 SME partners in the consortium, there may be commercial entities already positioned to offer the technology or sub-license components.

Can the scaffolds be produced at industrial scale?

The project objective explicitly states that the proposal seeks to provide fabricated reproducible scaffolds that can be produced on a large scale. The consortium includes 3 industry partners (43% industry ratio) across 3 countries, suggesting manufacturing scale-up was a design goal. However, no specific production volume numbers are available in the data.

What is the IP situation — who owns the results?

The project was funded under FETOPEN-RIA (Research and Innovation Action), where IP typically stays with the consortium partners who generated it. With 7 partners including 3 SMEs, IP is likely shared. Aston University as coordinator would be the first point of contact for licensing inquiries.

How far is this from a product I can buy or use?

This is a FET Open project, meaning it was funded as high-risk frontier research. The team produced a working physiological chamber and 3D neural network platform with 12 deliverables total, but this remains at the research-to-prototype stage. Commercial availability would require further engineering, regulatory clearance, and manufacturing scale-up.

Does this comply with regulations for drug testing?

Based on available project data, specific regulatory validation (e.g., FDA or EMA acceptance for preclinical testing) is not mentioned. However, the platform uses human stem cell-derived tissue, which aligns with the global push to reduce animal testing. Regulatory acceptance of organ-on-chip and tissue-model platforms is advancing, which could benefit adoption of this technology.

Can this integrate with our existing lab equipment and workflows?

The project developed a physiological chamber that supports electrical stimulation, simultaneous recording, and light sheet imaging — standard techniques in neuroscience labs. This suggests the platform was designed to work with existing electrophysiology and imaging equipment. Specific compatibility details would need to be discussed with the consortium.

Consortium

Who built it

The MESO_BRAIN consortium brings together 7 partners from 3 countries (Germany, Spain, UK), with a strong industry presence: 3 SMEs make up 43% of the partnership, alongside 2 universities and 2 research organizations. This balanced mix signals that the project was designed with commercial translation in mind, not just academic publication. Aston University (UK) coordinates, providing academic credibility in neuroscience, while the 3 industrial partners likely contributed manufacturing expertise for scaffold fabrication and chamber engineering. For a business considering this technology, the presence of SME partners means there may already be companies positioned to commercialize specific components of the platform.

ASTON UNIVERSITYCoordinator · UK
FUNDACIO INSTITUT DE CIENCIES FOTONIQUESparticipant · ES
DLM CONSULTANCY SERVICES LTDparticipant · UK
UNIVERSITAT DE BARCELONAparticipant · ES
KITE INNOVATION (EUROPE) LIMITEDparticipant · UK
LZH LASERZENTRUM HANNOVER EVparticipant · DE
AXOL BIOSCIENCE LTDparticipant · UK

How to reach the team

Aston University, Birmingham, UK — contact via university technology transfer office

Order a report on this consortium See ASTON UNIVERSITY profile →

Next steps

Talk to the team behind this work.

Want an introduction to the MESO_BRAIN team? SciTransfer can connect you with the right consortium partner for your specific use case — drug screening, scaffold licensing, or research collaboration.

Order a report on this topic More in Health & Biomedical